Orthopediatrics (KIDS) Stock Rating Lowered by BidaskClub

Orthopediatrics (NASDAQ:KIDS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Thursday.

A number of other equities analysts have also weighed in on KIDS. Zacks Investment Research lowered shares of Orthopediatrics from a “buy” rating to a “hold” rating in a research note on Saturday, November 3rd. ValuEngine raised shares of Orthopediatrics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $31.33.

NASDAQ KIDS traded down $0.83 on Thursday, reaching $28.88. The company had a trading volume of 28,673 shares, compared to its average volume of 44,486. The firm has a market cap of $380.76 million and a PE ratio of -5.07. The company has a current ratio of 5.67, a quick ratio of 3.23 and a debt-to-equity ratio of 0.62. Orthopediatrics has a 1-year low of $14.00 and a 1-year high of $39.81.

Orthopediatrics (NASDAQ:KIDS) last announced its earnings results on Wednesday, October 31st. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $15.82 million during the quarter, compared to analyst estimates of $15.19 million. Orthopediatrics had a negative return on equity of 65.26% and a negative net margin of 55.97%. Orthopediatrics’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.70) earnings per share. Equities research analysts forecast that Orthopediatrics will post -0.95 EPS for the current year.

In other Orthopediatrics news, Director Kevin Unger sold 1,000 shares of the business’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $33.22, for a total transaction of $33,220.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 9,525 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $33.73, for a total transaction of $321,278.25. The disclosure for this sale can be found here. 46.10% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the business. Sei Investments Co. bought a new stake in shares of Orthopediatrics in the 2nd quarter valued at about $126,000. Rhumbline Advisers bought a new stake in shares of Orthopediatrics in the 3rd quarter valued at about $207,000. Regal Investment Advisors LLC bought a new stake in shares of Orthopediatrics in the 3rd quarter valued at about $246,000. Indiana Trust & Investment Management CO bought a new stake in shares of Orthopediatrics in the 3rd quarter valued at about $248,000. Finally, Paradigm Capital Management Inc. NY bought a new stake in shares of Orthopediatrics in the 2nd quarter valued at about $280,000. 40.22% of the stock is currently owned by hedge funds and other institutional investors.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Further Reading: What is a stock split?

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply